Cannabis remains a Schedule 1 controlled substance under UK law — defined as having no therapeutic value. This classification, which contradicts the reality that cannabis-based medicines are prescribed to tens of thousands of patients, has become one of the most contentious issues in UK drug policy.
The contradiction
The Schedule 1 classification is increasingly difficult to defend. Cannabis-based medicines are licensed, prescribed, and dispensed through the UK healthcare system. They are subject to MHRA regulation, NICE guidance, and CQC oversight. Classifying them alongside drugs with no accepted medical use creates a paradox that undermines the credibility of the scheduling system.
Calls for reform
A coalition of medical bodies, patient groups, and MPs has called for cannabis to be rescheduled to Schedule 2, which would acknowledge its therapeutic value while maintaining appropriate controls. The government has so far resisted these calls, citing international treaty obligations and public health concerns.
What's at stake
The scheduling debate is not academic. The Schedule 1 classification has real-world consequences: it deters research, complicates prescribing, and stigmatises patients. Rescheduling would send a clear signal that medical cannabis is a legitimate part of the UK healthcare system.
